Nab-paclitaxel + durvalumab as second- or third-line treatment of advanced NSCLC: results from ABOUND.2l+
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Conference item |
| Language: | English |
| Published: |
Elsevier
2017
|
| _version_ | 1797052002092449792 |
|---|---|
| author | Govindan, R Dols, MC Aix, S Postmus, PE Lewanski, C Bennouna, J Fischer, J Vidal, O Stewart, D Ardizoni, A Weaver, J Wolfsteiner, M Reck, M Talbot, D Morgensztern, D Ong, TJ |
| author_facet | Govindan, R Dols, MC Aix, S Postmus, PE Lewanski, C Bennouna, J Fischer, J Vidal, O Stewart, D Ardizoni, A Weaver, J Wolfsteiner, M Reck, M Talbot, D Morgensztern, D Ong, TJ |
| author_sort | Govindan, R |
| collection | OXFORD |
| description | |
| first_indexed | 2024-03-06T18:26:52Z |
| format | Conference item |
| id | oxford-uuid:08466862-d1c4-4613-b561-21cde79981d7 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:26:52Z |
| publishDate | 2017 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:08466862-d1c4-4613-b561-21cde79981d72022-03-26T09:12:09ZNab-paclitaxel + durvalumab as second- or third-line treatment of advanced NSCLC: results from ABOUND.2l+Conference itemhttp://purl.org/coar/resource_type/c_5794uuid:08466862-d1c4-4613-b561-21cde79981d7EnglishSymplectic ElementsElsevier2017Govindan, RDols, MCAix, SPostmus, PELewanski, CBennouna, JFischer, JVidal, OStewart, DArdizoni, AWeaver, JWolfsteiner, MReck, MTalbot, DMorgensztern, DOng, TJ |
| spellingShingle | Govindan, R Dols, MC Aix, S Postmus, PE Lewanski, C Bennouna, J Fischer, J Vidal, O Stewart, D Ardizoni, A Weaver, J Wolfsteiner, M Reck, M Talbot, D Morgensztern, D Ong, TJ Nab-paclitaxel + durvalumab as second- or third-line treatment of advanced NSCLC: results from ABOUND.2l+ |
| title | Nab-paclitaxel + durvalumab as second- or third-line treatment of advanced NSCLC: results from ABOUND.2l+ |
| title_full | Nab-paclitaxel + durvalumab as second- or third-line treatment of advanced NSCLC: results from ABOUND.2l+ |
| title_fullStr | Nab-paclitaxel + durvalumab as second- or third-line treatment of advanced NSCLC: results from ABOUND.2l+ |
| title_full_unstemmed | Nab-paclitaxel + durvalumab as second- or third-line treatment of advanced NSCLC: results from ABOUND.2l+ |
| title_short | Nab-paclitaxel + durvalumab as second- or third-line treatment of advanced NSCLC: results from ABOUND.2l+ |
| title_sort | nab paclitaxel durvalumab as second or third line treatment of advanced nsclc results from abound 2l |
| work_keys_str_mv | AT govindanr nabpaclitaxeldurvalumabassecondorthirdlinetreatmentofadvancednsclcresultsfromabound2l AT dolsmc nabpaclitaxeldurvalumabassecondorthirdlinetreatmentofadvancednsclcresultsfromabound2l AT aixs nabpaclitaxeldurvalumabassecondorthirdlinetreatmentofadvancednsclcresultsfromabound2l AT postmuspe nabpaclitaxeldurvalumabassecondorthirdlinetreatmentofadvancednsclcresultsfromabound2l AT lewanskic nabpaclitaxeldurvalumabassecondorthirdlinetreatmentofadvancednsclcresultsfromabound2l AT bennounaj nabpaclitaxeldurvalumabassecondorthirdlinetreatmentofadvancednsclcresultsfromabound2l AT fischerj nabpaclitaxeldurvalumabassecondorthirdlinetreatmentofadvancednsclcresultsfromabound2l AT vidalo nabpaclitaxeldurvalumabassecondorthirdlinetreatmentofadvancednsclcresultsfromabound2l AT stewartd nabpaclitaxeldurvalumabassecondorthirdlinetreatmentofadvancednsclcresultsfromabound2l AT ardizonia nabpaclitaxeldurvalumabassecondorthirdlinetreatmentofadvancednsclcresultsfromabound2l AT weaverj nabpaclitaxeldurvalumabassecondorthirdlinetreatmentofadvancednsclcresultsfromabound2l AT wolfsteinerm nabpaclitaxeldurvalumabassecondorthirdlinetreatmentofadvancednsclcresultsfromabound2l AT reckm nabpaclitaxeldurvalumabassecondorthirdlinetreatmentofadvancednsclcresultsfromabound2l AT talbotd nabpaclitaxeldurvalumabassecondorthirdlinetreatmentofadvancednsclcresultsfromabound2l AT morgenszternd nabpaclitaxeldurvalumabassecondorthirdlinetreatmentofadvancednsclcresultsfromabound2l AT ongtj nabpaclitaxeldurvalumabassecondorthirdlinetreatmentofadvancednsclcresultsfromabound2l |